Nature Communications (May 2022)
A topological refactoring design strategy yields highly stable granulopoietic proteins
- Julia Skokowa,
- Birte Hernandez Alvarez,
- Murray Coles,
- Malte Ritter,
- Masoud Nasri,
- Jérémy Haaf,
- Narges Aghaallaei,
- Yun Xu,
- Perihan Mir,
- Ann-Christin Krahl,
- Katherine W. Rogers,
- Kateryna Maksymenko,
- Baubak Bajoghli,
- Karl Welte,
- Andrei N. Lupas,
- Patrick Müller,
- Mohammad ElGamacy
Affiliations
- Julia Skokowa
- Division of Translational Oncology, Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen
- Birte Hernandez Alvarez
- Max Planck Institute for Biology
- Murray Coles
- Max Planck Institute for Biology
- Malte Ritter
- Division of Translational Oncology, Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen
- Masoud Nasri
- Division of Translational Oncology, Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen
- Jérémy Haaf
- Division of Translational Oncology, Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen
- Narges Aghaallaei
- Division of Translational Oncology, Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen
- Yun Xu
- Division of Translational Oncology, Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen
- Perihan Mir
- Division of Translational Oncology, Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen
- Ann-Christin Krahl
- Division of Translational Oncology, Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen
- Katherine W. Rogers
- Friedrich Miescher Laboratory of the Max Planck Society
- Kateryna Maksymenko
- Max Planck Institute for Biology
- Baubak Bajoghli
- Division of Translational Oncology, Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen
- Karl Welte
- Division of Translational Oncology, Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen
- Andrei N. Lupas
- Max Planck Institute for Biology
- Patrick Müller
- Friedrich Miescher Laboratory of the Max Planck Society
- Mohammad ElGamacy
- Division of Translational Oncology, Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen
- DOI
- https://doi.org/10.1038/s41467-022-30157-2
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 17
Abstract
Skokowa et al. reconstruct the fold of a granulopoietic cytokine, resulting in de novo, hyperstable, highly active proteins with therapeutic potential for treating several neutropenia disorders.
